BRPI0720158A2 - Agentes para terapia e/ou melhora de coagulação intravascular disseminada, para reduzir a probabilidade de morte em pacientes sofrendo da mesma, métodos para selecionar pacientes, e, para tratar e/ou melhorar coagulação intravascular disseminada - Google Patents

Agentes para terapia e/ou melhora de coagulação intravascular disseminada, para reduzir a probabilidade de morte em pacientes sofrendo da mesma, métodos para selecionar pacientes, e, para tratar e/ou melhorar coagulação intravascular disseminada

Info

Publication number
BRPI0720158A2
BRPI0720158A2 BRPI0720158-3A2A BRPI0720158A BRPI0720158A2 BR PI0720158 A2 BRPI0720158 A2 BR PI0720158A2 BR PI0720158 A BRPI0720158 A BR PI0720158A BR PI0720158 A2 BRPI0720158 A2 BR PI0720158A2
Authority
BR
Brazil
Prior art keywords
intravascular coagulation
patients
death
probability
treat
Prior art date
Application number
BRPI0720158-3A2A
Other languages
English (en)
Inventor
Yoshikazu Aoki
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of BRPI0720158A2 publication Critical patent/BRPI0720158A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0720158-3A2A 2006-10-06 2007-10-05 Agentes para terapia e/ou melhora de coagulação intravascular disseminada, para reduzir a probabilidade de morte em pacientes sofrendo da mesma, métodos para selecionar pacientes, e, para tratar e/ou melhorar coagulação intravascular disseminada BRPI0720158A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006274573 2006-10-06
PCT/JP2007/069560 WO2008044631A1 (en) 2006-10-06 2007-10-05 Therapeutic and/or ameliorating agent for disseminated intravascular coagulation

Publications (1)

Publication Number Publication Date
BRPI0720158A2 true BRPI0720158A2 (pt) 2014-05-20

Family

ID=39282827

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720158-3A2A BRPI0720158A2 (pt) 2006-10-06 2007-10-05 Agentes para terapia e/ou melhora de coagulação intravascular disseminada, para reduzir a probabilidade de morte em pacientes sofrendo da mesma, métodos para selecionar pacientes, e, para tratar e/ou melhorar coagulação intravascular disseminada

Country Status (16)

Country Link
US (1) US20100152106A1 (pt)
EP (1) EP2062589A4 (pt)
JP (1) JP5579385B2 (pt)
KR (1) KR20090051777A (pt)
CN (1) CN101522206B (pt)
AU (1) AU2007305550B2 (pt)
BR (1) BRPI0720158A2 (pt)
CA (1) CA2665691A1 (pt)
CO (1) CO6160332A2 (pt)
IL (1) IL197509A (pt)
MX (1) MX2009003384A (pt)
MY (1) MY148565A (pt)
NZ (1) NZ575632A (pt)
RU (1) RU2433829C2 (pt)
UA (1) UA97961C2 (pt)
WO (1) WO2008044631A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2743141A1 (en) * 2008-11-12 2010-05-20 Eli Lilly And Company Compositions and methods of use for soluble thrombomodulin variants
WO2020067389A1 (ja) * 2018-09-28 2020-04-02 旭化成ファーマ株式会社 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
EP3871684B1 (en) * 2018-10-22 2024-06-26 Asahi Kasei Pharma Corporation Drug for treating and/or improving septicemia associated with coagulation abnormality
RU2716492C1 (ru) * 2019-05-14 2020-03-12 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ регулирования активации нейтрофилов в модели in vitro

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816494A1 (en) * 1987-01-08 1998-01-07 Asahi Kasei Kogyo Kabushiki Kaisha DNA coding for a peptide promoting the activation of protein C by thrombin, and process for producing the same
DE3876124T2 (de) 1987-04-01 1993-05-06 Mitsubishi Gas Chemical Co Immunoassay fuer thrombomodulin.
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS646219U (pt) 1987-06-30 1989-01-13
JPS6445398U (pt) 1987-09-11 1989-03-20
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
US5202421A (en) * 1988-12-27 1993-04-13 Mochida Pharmaceutical Co., Ltd. Anticoagulant substance obtained from urine and process for the preparation thereof
JPH0798840B2 (ja) 1988-12-27 1995-10-25 持田製薬株式会社 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
CA2022713A1 (en) 1989-08-11 1991-02-12 Nils U. Bang Human thrombomodulin derivatives
JPH03259084A (ja) 1990-03-06 1991-11-19 Kowa Co トロンビン結合性物質の製造法
JP3189052B2 (ja) * 1990-06-27 2001-07-16 持田製薬株式会社 抗血液凝固活性を有するポリペプチド
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
KR930008093B1 (ko) * 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
EP0544826B1 (en) 1990-08-15 2002-01-02 Paion GmbH Superior thrombomodulin analogs for pharmaceutical use
JP3220174B2 (ja) 1990-12-12 2001-10-22 第一製薬株式会社 組換ヒトトロンボモジュリン誘導体
ATE264913T1 (de) 1992-02-05 2004-05-15 Paion Gmbh Protease-resistente analoge des thrombomodulin
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
EP1476752A4 (en) * 2002-02-27 2008-02-13 Bio Merieux Inc METHOD FOR DIAGNOSING AND MONITORING HEMOSTATIC DYSFUNCTION, SEVERE INFECTION AND SYSTEMATIC INFLAMMATORY RESPONSE SYNDROME
HK1080372A1 (zh) * 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体

Also Published As

Publication number Publication date
CA2665691A1 (en) 2008-04-17
CN101522206A (zh) 2009-09-02
HK1130209A1 (en) 2009-12-24
EP2062589A1 (en) 2009-05-27
IL197509A (en) 2015-06-30
AU2007305550A1 (en) 2008-04-17
WO2008044631A1 (en) 2008-04-17
CN101522206B (zh) 2013-03-27
NZ575632A (en) 2011-12-22
UA97961C2 (ru) 2012-04-10
EP2062589A4 (en) 2010-07-28
IL197509A0 (en) 2011-08-01
JP5579385B2 (ja) 2014-08-27
RU2009117253A (ru) 2010-11-20
AU2007305550B2 (en) 2010-09-30
RU2433829C2 (ru) 2011-11-20
US20100152106A1 (en) 2010-06-17
KR20090051777A (ko) 2009-05-22
CO6160332A2 (es) 2010-05-20
MY148565A (en) 2013-04-30
MX2009003384A (es) 2009-04-08
JPWO2008044631A1 (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
BRPI0720178A2 (pt) Derivados de 2,3-di-hidroimidazo[1,2-c]quinazolina substituída úteis para tratar distúrbios e doenças hiperproliferativos associados com angiogênese
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2009068659A3 (en) Novel disease treatment by predicting drug association
BRPI1006115A2 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
WO2009064444A9 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
PT2796457T (pt) Genz 112638 para o tratamento de doença de gaucher ou de fabry em terapia de associação
EP2046315A4 (en) THERAPEUTIC AGENTS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES
BRPI0816382A2 (pt) Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
BRPI0812755A2 (pt) Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BRPI0922452A2 (pt) composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
BRPI0922817A2 (pt) corpo médico absorvente, em particular para remoção de fluidos de feridas de cavidades do corpo humano e/ou de um animal e métodos para sua produção
NO20075527L (no) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2009149106A3 (en) Microparticles for the treatment of disease
BRPI0718041A2 (pt) Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
BRPI0910737A2 (pt) composto, pró-droga, agente farmacêutico, método para profilaxia ou tratamento de doenças do trato urinário inferior em um mamífero, e, uso de um composto ou uma pró-droga do mesmo.
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
ATE543492T1 (de) Behandlung von lungenkrebs
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2008048996A3 (en) Sequential combination therapy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL